Profound Medical to Release Second Quarter 2024 Financial Results on August 8

Core Insights - Profound Medical Corp. is set to announce its second quarter 2024 financial results on August 8, 2024, after market close [4] - The company is actively commercializing innovative medical technologies, including Sonalleve® and TULSA-PRO®, aimed at non-invasive treatment of various medical conditions [3][6] Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on developing and marketing customizable, incision-free therapies for the ablation of diseased tissue [4][7] - The company has received CE marking, Health Canada approval, and FDA clearance for its technologies, indicating compliance with regulatory standards [6] Product Developments - Sonalleve® is a therapeutic platform approved for treating uterine fibroids and palliative pain from bone metastases, with potential applications in non-invasive ablation of abdominal cancers [3] - TULSA-PRO® combines real-time MRI and ultrasound technology for customizable prostate ablation, with applications in various stages of prostate cancer and benign prostatic hyperplasia [6]